Results 161 to 170 of about 20,467 (242)

Using Pharmacovigilance Data for Signal Detection of Drug Interactions for Rosuvastatin

Basic &Clinical Pharmacology &Toxicology, Volume 139, Issue 2, August 2026.
ABSTRACT The 3‐hydroxy‐3‐methyl‐glutaryl‐coenzyme A reductase inhibitor rosuvastatin is a substrate of breast cancer resistance protein (BCRP). BCRP inhibition increases rosuvastatin plasma concentrations and may result in concentration‐dependent muscle toxicity, at worst rhabdomyolysis.
Ronja Levomäki, Päivi Hirvensalo, Aleksi Tornio, Anne M. Filppula   +3 more
wiley   +1 more source

Parallel screening strategies reveal distinct phenotypic and genotypic profiles of familial hypercholesterolemia in children and adults. [PDF]

Atheroscler Plus
Sikonja J, Intihar U, Jug B, Salobir N, Trebusak Podkrajsek K, Cevc M, Dordevic N, Kafol J, Gorjanc T, Mlinaric M, Cugalj Kern B, Kovac J, Battelino T, Fras Z, Groselj U.   +14 more
europepmc   +1 more source

AP‐1B Controls Several Levels of Cell Proliferation and Differentiation in Mouse Enteroids

Biology of the Cell, Volume 118, Issue 8, August 2026.
We show that in mouse intestinal organoids, AP‐1B is implicated in apical polarity, differentiation in the secretory lineage and proliferation. In particular, we propose that proliferation is controlled by AP‐1B via the mTOR and YAP pathways. Arrows show the functional links that were elucidated in this study, and dotted lines show putative downstream ...
Maela Duclos, Anne Bourdais, Ophélie Nicolle, Alexandre Helpiquet, Grégoire Michaux, Aurélien Bidaud‐Meynard   +5 more
wiley   +1 more source

Missed and Misdiagnosed: Precision Medicine Approaches to Screening for Familial Hypercholesterolemia and Lipoprotein(a). [PDF]

JACC Adv
Helm BM, Huerta V, Clary JM.
europepmc   +1 more source

Development and analytical validation of a targeted short‐read next generation sequencing‐based pharmacogenetic panel for comprehensive variant detection

British Journal of Pharmacology, Volume 183, Issue 16, Page 4735-4760, August 2026.
Abstract Background and Purpose Genomic profiling of patients for genetic variants that modify the effect of specific medications has many benefits, including the possibility of avoiding toxicities and ensuring an adequate effect of the medication. Our intention was to develop a comprehensive, high‐quality pharmacogenetic test panel for clinical use ...
Anna Gréen, Nils Johan Fredriksson, Michael Andresen, Jon Jonasson, Malin Lindqvist Appell, Henrik Gréen   +5 more
wiley   +1 more source

Therapeutic Plasma Exchange and Evinacumab for Homozygous Familial Hypercholesterolemia. [PDF]

JACC Case Rep
Raygani S, Sykes AV, Sanchez AP, Witztum JL, Wilkinson MJ.   +4 more
europepmc   +1 more source

Jiuwei Xiaozhi Decoction Alleviates High‐Fat Diet‐Induced MASLD by Suppressing Hepatic SREBP2‐Driven Cholesterogenesis and Restoring PPARα‐Mediated Fatty Acid Oxidation

Chemical Biology &Drug Design, Volume 108, Issue 2, August 2026.
Studies have found that Jiuwei Xiaozhi Decoction can improve high‐fat diet‐induced fatty liver disease, mainly by regulating the SREBP2 and PPARα pathways to balance hepatic lipid metabolism while reducing inflammatory responses. ABSTRACT Jiuwei Xiaozhi Decoction (JWXZ) is a nine‐herb traditional Chinese medicine formula clinically used for hepatic ...
Youcheng Ma, Xinrui Gao, Ji Wang, Lingru Li, Zhen Huang, Fangli Li   +5 more
wiley   +1 more source

Consequences of Late Diagnosis and Insufficient Cholesterol Treatment in Women With Heterozygous Familial Hypercholesterolemia. [PDF]

JACC Case Rep
Santos RD.
europepmc   +1 more source

A Comprehensive Evaluation of Adiposity Indices on 20‐Year Cumulative Incidence of Type 2 Diabetes: The ATTICA Cohort Study (2002–2022)

Clinical Obesity, Volume 16, Issue 4, August 2026.
ABSTRACT The aim of this study was to evaluate the association between indices of adiposity and 20‐year cumulative incidence of type 2 diabetes (T2D) among apparently healthy adults participating in the ATTICA cohort study (2002–2022). The present analysis included data from 2000 individuals free of atherosclerotic cardiovascular disease (ASCVD) and ...
Ioanna Kechagia, Sofia‐Panagiota Giannakopoulou, Fotios Barkas, Mary Yannakoulia, Evangelos Liberopoulos, Petros P. Sfikakis, Christos Pitsavos, Demosthenes Panagiotakos   +7 more
wiley   +1 more source

Improving the clinical diagnosis of familial hypercholesterolemia among patients attending diabetes and cardiology clinics. [PDF]

Am J Prev Cardiol
Toor SM, Akyea RK, Mohammed S, Al Hail MSH, El-Menyar A, Gomaa M, Jayyousi A, Al Suwaidi JM, Qureshi N, Albagha OME.   +9 more
europepmc   +1 more source